Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma
P. Mondello, S. Tadros, M. Teater, L. Fontan, A. Chang, N. Jain, S. Singh, M. C. J. Ma, H. Yang, E. Toska, S. Alig, M. Durant, E. de Stanchina, A. Mottok, L. Nastoupil, , M. Green
This paper shows that HDAC3 inhibitors reverse CREBBP mutation-driven epigenetic changes in lymphoma, inhibiting tumor growth and restoring immune surveillance.
bioRxiv · Jan 27, 2019Cancer Biology